Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescence analysis of EGFR was done on 90% confluent log phase A431 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled EGFR (H11) Mouse Monoclonal Antibody (MA112693) at 2ug/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d is a merged image showing membranous localization. Panel e is a no primary antibody control. The images were captured at 60X magnification.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human, Mouse, Not Applicable|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||HC2 20 d2 cells.|
|Storage buffer||PBS, pH 7.4|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay Dependent|
|Immunofluorescence (IF)||1-2 µg/ml|
|Immunohistochemistry (Paraffin) (IHC (P))||2-4 µg/ml|
|Immunoprecipitation (IP)||2 µg/mg lysate|
|Western Blot (WB)||0.5-1 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunocytochemistry (ICC)||See 4 publications below|
|Blocking Assay (BLOCK)||See 2 publications below|
|Western Blot (WB)||See 26 publications below|
|Immunoprecipitation (IP)||See 3 publications below|
|Immunohistochemistry (IHC)||See 1 publications below|
|Flow Cytometry (Flow)||See 3 publications below|
|ELISA (ELISA)||See 2 publications below|
|Gel Shift (GS)||See 1 publications below|
MA1-12693 detects Epidermal Growth Factor Receptor in human samples.
MA1-12693 has been successfully used in FACS, immunofluorescence, immunoprecipitation, Western blot, and immunohistochemistry (paraffin) procedures. Staining of formalin-fixed tissues requires digestion with protease xxv at 1 mg/ml in PBS for 5 minutes at 37°C. Positive controls include A431 cells or placenta or squamous cell carcinoma. Suitable for Western blotting of extracellular domain of EGFR.
The MA1-12693 immunogen is HC2 20 d2 cells.
The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. Multiple alternatively spliced transcript variants that encode different protein isoforms have been found for this gene.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Multilayered, Hyaluronic Acid-Based Hydrogel Formulations Suitable for Automated 3D High Throughput Drug Screening of Cancer-Stromal Cell Cocultures.
MA1-12693 was used in immunocytochemistry to use a high-throughput 3D hyaluronic acid hydrogel coculture of cancer cells with stromal cells to evaluate chemotherapeutics
|Engel BJ,Constantinou PE,Sablatura LK,Doty NJ,Carson DD,Farach-Carson MC,Harrington DA,Zarembinski TI||Advanced healthcare materials (4:1664)||2015|
Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
MA1-12693 was used in immunocytochemistry to study the efficacy and anti-prolifferative mechanism of Proellex in breast cancer cells overexpressing aromatase and resistant to Letrozole
|Gupta A,Mehta R,Alimirah F,Peng X,Murillo G,Wiehle R,Mehta RG||The Journal of steroid biochemistry and molecular biology (133:30)||2013|
Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept.
MA1-12693 was used in immunocytochemistry to develop a process involving leukapheresis, elutriation and FACS to isolate circulating tumor cells from large volumes
|Eifler RL,Lind J,Falkenhagen D,Weber V,Fischer MB,Zeillinger R||Cytometry. Part B, Clinical cytometry (80:100)||2011|
EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.
MA1-12693 was used in immunocytochemistry to study EGF-independent activation of mutant cell-surface EGF receptors in gefitinib-sensitive lung cancer
|Choi SH,Mendrola JM,Lemmon MA||Oncogene (26:1567)||2007|
Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.
MA1-12693 was used in blocking or activating experiment to study the therapeutic effects against cetuximab-resistant BRAF and KRAS mutant tumors of an antibody fusion protein that recognizes three EGFR epitopes
|Spangler JB,Manzari MT,Rosalia EK,Chen TF,Wittrup KD||Journal of molecular biology (422:532)||2012|
Design of surfaces for liquid crystal-based bioanalytical assays.
MA1-12693 was used in blocking or activating experiment to investigate the liquid crystal-based bioanalytical assays
|Lowe AM,Ozer BH,Bai Y,Bertics PJ,Abbott NL||ACS applied materials and interfaces (2:722)||2010|
Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma.
MA1-12693 was used in western blot to investigate the relationship between SGLT1 and EGFR gene expression and tumor differetiation in oral squamous cell carcinoma
|Hanabata Y,Nakajima Y,Morita K,Kayamori K,Omura K||Odontology (100:156)||2012|
Overexpression of cortactin increases invasion potential in oral squamous cell carcinoma.
MA1-12693 was used in western blot to study the role of cortactin overexpression in increasing invasion potential in oral squamous cell carcinoma
|Yamada S,Yanamoto S,Kawasaki G,Mizuno A,Nemoto TK||Pathology oncology research : POR (16:523)||2010|
Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways.
MA1-12693 was used in western blot to determine the minimal period of melatonin treatment required to induce the differentiation of human mesenchymal stem cells into osteoblasts
|Sethi S,Radio NM,Kotlarczyk MP,Chen CT,Wei YH,Jockers R,Witt-Enderby PA||Journal of pineal research (49:222)||2010|
Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR.
MA1-12693 was used in western blot to study the expression of PTEN, Mcl-1 and EGFR in non-small cell lung cancer
|Cetin Z,Ozbilim G,Erdogan A,Luleci G,Karauzum SB||Medical oncology (Northwood, London, England) (27:853)||2010|
Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
MA1-12693 was used in western blot to study the increased anti-tumor activity of simultaneous inhibition of NF-kappaB, Cox-2, and EGFR in pancreatic cancer
|Ali S,Banerjee S,Schaffert JM,El-Rayes BF,Philip PA,Sarkar FH||Journal of cellular biochemistry (110:171)||2010|
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.
MA1-12693 was used in western blot to study the effect of miR-200 expression on the epithelial-to-mesenchymal transition and resistance to EGFR therapy in bladder cancer cells
|Adam L,Zhong M,Choi W,Qi W,Nicoloso M,Arora A,Calin G,Wang H,Siefker-Radtke A,McConkey D,Bar-Eli M,Dinney C||Clinical cancer research : an official journal of the American Association for Cancer Research (15:5060)||2009|
Sennoside B inhibits PDGF receptor signaling and cell proliferation induced by PDGF-BB in human osteosarcoma cells.
MA1-12693 was used in western blot to study the role of PDGF signaling in the inhibition of osteosarcoma cell proliferation by sennoside B
|Chen YC,Chang CN,Hsu HC,Chiou SJ,Lee LT,Hseu TH||Life sciences (84:915)||2009|
Erlotinib and bevacizumab have synergistic activity against melanoma.
MA1-12693 was used in western blot to study the effect of combined treatment with erlotinib and bevacizumab against melanoma
|Schicher N,Paulitschke V,Swoboda A,Kunstfeld R,Loewe R,Pilarski P,Pehamberger H,Hoeller C||Clinical cancer research : an official journal of the American Association for Cancer Research (15:3495)||2009|
Proteomic and immunologic analyses of brain tumor exosomes.
MA1-12693 was used in western blot to investigate brain tumor exosomes by biochemical, proteomic, and immunological approaches
|Graner MW,Alzate O,Dechkovskaia AM,Keene JD,Sampson JH,Mitchell DA,Bigner DD||FASEB journal : official publication of the Federation of American Societies for Experimental Biology (23:1541)||2009|
Overexpression of JKTBP1 induces androgen-independent LNCaP cell proliferation through activation of epidermal growth factor-receptor (EGF-R).
MA1-12693 was used in western blot to investigate the effect of heterogenous nuclear ribonucleoprotein D-like protein on androgen-independent LNCaP cell proliferation
|Wu YY,Li H,Lv XY,Wei Q,Li X,Liu XY,Zhou Q,Wei YQ||Cell biochemistry and function (26:467)||2008|
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells.
MA1-12693 was used in western blot to study molecular markers of the response to cetuximab therapy in a panel of urothelial carcinoma cell lines
|Black PC,Brown GA,Inamoto T,Shrader M,Arora A,Siefker-Radtke AO,Adam L,Theodorescu D,Wu X,Munsell MF,Bar-Eli M,McConkey DJ,Dinney CP||Clinical cancer research : an official journal of the American Association for Cancer Research (14:1478)||2008|
Radiotherapy response in oral squamous carcinoma cell lines: evaluation of apoptotic proteins as prognostic factors.
MA1-12693 was used in western blot to investigate the effect of apoptotic proteins on the radiosensitivity of oral squamous carcinoma cell line
|Roberg K,Jonsson AC,Grénman R,Norberg-Spaak L||Head and neck (29:325)||2007|
Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05.
MA1-12693 was used in western blot to study the EGFR-targeting potential of novel triazolinium-containing "combi-molecules
|Qiu Q,Domarkas J,Banerjee R,Katsoulas A,McNamee JP,Jean-Claude BJ||Anti-cancer drugs (18:171)||2007|
Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17.
MA1-12693 was used in western blot to study the effect of ADAM17 silencing on multiple acquired renal carcinoma tumor capabilities
|Franovic A,Robert I,Smith K,Kurban G,Pause A,Gunaratnam L,Lee S||Cancer research (66:8083)||2006|
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.
MA1-12693 was used in western blot to study the efficacy of a dual PI3 kinase/mTOR inhibitor in glioma
|Fan QW,Knight ZA,Goldenberg DD,Yu W,Mostov KE,Stokoe D,Shokat KM,Weiss WA||Cancer cell (9:341)||2006|
Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer.
MA1-12693 was used in western blot to study the role of estrogen receptors in membrane lipid rafts in breast cancer signal transduction
|Márquez DC,Chen HW,Curran EM,Welshons WV,Pietras RJ||Molecular and cellular endocrinology (246:91)||2006|
Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
MA1-12693 was used in western blot to investigate the effect of a novel toll-like receptor 9 agonist on epidermal growth factor receptor inhibition and on tumor growth
|Damiano V,Caputo R,Bianco R,D'Armiento FP,Leonardi A,De Placido S,Bianco AR,Agrawal S,Ciardiello F,Tortora G||Clinical cancer research : an official journal of the American Association for Cancer Research (12:577)||2006|
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
MA1-12693 was used in western blot to study the mechanism of resistance to the EGFR tyrosine kinase inhibitor Gefitinib in bladder cancer cells
|Kassouf W,Dinney CP,Brown G,McConkey DJ,Diehl AJ,Bar-Eli M,Adam L||Cancer research (65:10524)||2005|
Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo.
MA1-12693 was used in western blot to study whether gene silencing by vector-mediated RNAi inhibition of EGFR expression can reduce the growth of cultured human glioma cells
|Saydam O,Glauser DL,Heid I,Turkeri G,Hilbe M,Jacobs AH,Ackermann M,Fraefel C||Molecular therapy : the journal of the American Society of Gene Therapy (12:803)||2005|
The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo.
MA1-12693 was used in western blot to study the anti-tumor mechanism of a unimolecular combination of an EGFR tyrosine kinase inhibitor and a DNA damaging triazine
|Matheson SL,McNamee JP,Wang T,Alaoui-Jamali MA,Tari AM,Jean-Claude BJ||The Journal of pharmacology and experimental therapeutics (311:1163)||2004|
Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility.
MA1-12693 was used in western blot to study the role of a constitutively active variant of the EGFR in increasing mouse fibroblast motility
|Pedersen MW,Tkach V,Pedersen N,Berezin V,Poulsen HS||International journal of cancer (108:643)||2004|
Neuregulin expression, function, and signaling in human ovarian cancer cells.
MA1-12693 was used in western blot to investigate the characteristics of neuregulin in human ovarian cancer cells
|Gilmour LM,Macleod KG,McCaig A,Sewell JM,Gullick WJ,Smyth JF,Langdon SP||Clinical cancer research : an official journal of the American Association for Cancer Research (8:3933)||2002|
Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.
MA1-12693 was used in western blot to study the inhibition of EGFR-mediated signaling by a "Combi-triazene" molecule with binary EGFR targeting/DNA-damaging properties
|Brahimi F,Matheson SL,Dudouit F,McNamee JP,Tari AM,Jean-Claude BJ||The Journal of pharmacology and experimental therapeutics (303:238)||2002|
Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype.
MA1-12693 was used in immunohistochemistry and western blot to study the role of EGFR mutation type III in enhancing the malignant phenotype in a small cell lung cancer cell line
|Damstrup L,Wandahl Pedersen M,Bastholm L,Elling F,Skovgaard Poulsen H||International journal of cancer (97:7)||2002|
Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
MA1-12693 was used in western blot to study the use of adenovirus-mediated overexpression of dominant negative EGFR to radiosensitize human carcinoma and malignant glioma cells
|Lammering G,Lin PS,Contessa JN,Hampton JL,Valerie K,Schmidt-Ullrich RK||International journal of radiation oncology, biology, physics (51:775)||2001|
Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells.
MA1-12693 was used in western blot to study the biological functions of the epidermal growth factor receptor and DNA-dependent protein kinase interaction
|Bandyopadhyay D,Mandal M,Adam L,Mendelsohn J,Kumar R||The Journal of biological chemistry (273:1568)||1998|
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
MA1-12693 was used in immunoprecipitation to investigate the state of HER1-HER2 interaction and modification in cell lines and tumors
|DeFazio-Eli L,Strommen K,Dao-Pick T,Parry G,Goodman L,Winslow J||Breast cancer research : BCR (13:null)||2011|
Engineering of PDMS surfaces for use in microsystems for capture and isolation of complex and biomedically important proteins: epidermal growth factor receptor as a model system.
MA1-12693 was used in immunoprecipitation to develop a novel system for capture and isolation of biomedically important proteins
|Lowe AM,Ozer BH,Wiepz GJ,Bertics PJ,Abbott NL||Lab on a chip (8:1357)||2008|
Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
MA1-12693 was used in immunoprecipitation to study the role and therapuetic potential of the EGFR type III in modulating cellular responses to ionizing radiation
|Lammering G,Hewit TH,Holmes M,Valerie K,Hawkins W,Lin PS,Mikkelsen RB,Schmidt-Ullrich RK||Clinical cancer research : an official journal of the American Association for Cancer Research (10:6732)||2004|
Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain.
MA1-12693 was used in immunohistochemistry to describe an EGF receptor mutant with tandem kinase domain duplication in glioblastoma multiforme biopsies and cell lines
|Ozer BH,Wiepz GJ,Bertics PJ||Oncogene (29:855)||2010|
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
MA1-12693 was used in flow cytometry to study the role of HER-2/neu overexpression in increasing the viable hypoxic cell population within solid tumors
|Dragowska WH,Warburton C,Yapp DT,Minchinton AI,Hu Y,Waterhouse DN,Gelmon K,Skov K,Woo J,Masin D,Huxham LA,Kyle AH,Bally MB||Molecular cancer research : MCR (2:606)||2004|
Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments.
MA1-12693 was used in flow cytometry to study the use of yeast surface display for identifying stable folded protein domains and characterizing antibody binding epitopes
|Cochran JR,Kim YS,Olsen MJ,Bhandari R,Wittrup KD||Journal of immunological methods (287:147)||2004|
Cell migration and MMP-9 secretion are increased by epidermal growth factor in HaCaT-ras transfected cells.
MA1-12693 was used in flow cytometry to study the effect of epidermal growth factor and HaCaT-ras on MMP-9 expression and cell migration
|Charvat S,Chignol MC,Souchier C,Le Griel C,Schmitt D,Serres M||Experimental dermatology (7:184)||1998|
|Not Applicable||Not Cited||
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
MA1-12693 was used in ELISA to suggest that AEE788 is an anticancer agent that deregulates tumor cell proliferation and angiogenic parameters
|Traxler P,Allegrini PR,Brandt R,Brueggen J,Cozens R,Fabbro D,Grosios K,Lane HA,McSheehy P,Mestan J,Meyer T,Tang C,Wartmann M,Wood J,Caravatti G||Cancer research (64:4931)||2004|
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.
MA1-12693 was used in ELISA to study the in vivo antitumor activity of a potent and selective IGF-1 receptor kinase inhibitor
|García-Echeverría C,Pearson MA,Marti A,Meyer T,Mestan J,Zimmermann J,Gao J,Brueggen J,Capraro HG,Cozens R,Evans DB,Fabbro D,Furet P,Porta DG,Liebetanz J,Martiny-Baron G,Ruetz S,Hofmann F||Cancer cell (5:231)||2004|
Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity.
MA1-12693 was used in EMSA to investigate the nucleophilic reactivity of natural antibodies
|Planque S,Taguchi H,Burr G,Bhatia G,Karle S,Zhou YX,Nishiyama Y,Paul S||The Journal of biological chemistry (278:20436)||2003|
avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; cell growth inhibiting protein 40; cell proliferation-inducing protein 61; epidermal growth f; Epidermal growth factor receptor; erb-b2 receptor tyrosine kinase 1; ERBB; ERBB1; HER1; mENA; PIG61; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; waved 2
9030024J15Rik; AI552599; EGFR; ERBB; ERBB1; Errb1; Errp; HER1; mENA; NISBD2; PIG61; wa-2; wa2; Wa5